Immunohistochemical (IHC) staining was used to quantify DDA1 levels as well as NFκB pathway activation, as measured by p65 nuclear translocation, in 101 relapsed and 178 nonrelapsed patients with stage II colon cancer. This evidence concerns the gene NFKB1 and malignant colon neoplasm.